Erin B. Noftall

Erin B. Noftall

Auto-generated profile, based on publicly available information

Erin B. Noftall

Department of Pathology, Dalhousie University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JRJanani Radhakrishnan
Janani Radhakrishnan
BKBarry E. Kennedy
Barry E. Kennedy
ENErin B. Noftall
Erin B. Noftall
CGCarman Giacomantonio
Carman Giacomantonio
H.P. Vasantha RupasingheH.P. Vasantha Rupasinghe
H.P. Vasantha Rupasinghe
Eczema (atopic dermatitis, AD) is a skin disease characterized by skin barrier dysfunction due to various factors, including genetics, immune system abnormalities, and environmental triggers. Application of emollients and topical drugs such as corticosteroids and calcineurin inhibitors form the mainstay of treatments for this challenging condition. This review aims to summarize the recent advances made in phytochemical-based topical applications to treat AD and the different carriers that are being used. In this review, the clinical efficacy of several plant extracts and bioactive phytochemical compounds in treating AD are discussed. The anti-atopic effects of the herbs are evident through improvements in the Scoring Atopic Dermatitis (SCORAD) index, reduced epidermal thickness, decreased transepidermal water loss, and alleviated itching and dryness in individuals affected by AD as well as in AD mouse models. Histopathological studies and serum analyses conducted in AD mouse models demonstrated a reduction in key inflammatory factors, including thymic stromal lymphopoietin (TSLP), serum immunoglobulin E (IgE), and interleukins (IL). Additionally, there was an observed upregulation of the filaggrin (FLG) gene, which regulates the proteins constituting the stratum corneum, the outermost layer of the epidermis. Carriers play a crucial role in topical drug applications, influencing dose delivery, retention, and bioavailability. This discussion delves into the efficacy of various nanocarriers, including liposomes, ethosomes, nanoemulsions, micelles, nanocrystals, solid-lipid nanoparticles, and polymeric nanoparticles. Consequently, the potential long-term side effects such as atrophy, eruptions, lymphoma, pain, and allergic reactions that are associated with current topical treatments, including emollients, topical corticosteroids, topical calcineurin inhibitors, and crisaborole, can potentially be mitigated through the use of phytochemical-based natural topical treatments.

10 October 2025 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
KCKate N. Clark
Kate N. Clark
BKBarry E. Kennedy
Barry E. Kennedy
CDCheryl Dean
Cheryl Dean
GSGeetha Subramanian
Geetha Subramanian
ENErin B. Noftall
Erin B. Noftall
CGCarman Giacomantonio
Carman Giacomantonio
Mild hyperthermia (42-48 °C) is a well-established therapeutic modality that can induce controlled tumor cell death and stimulate anti-cancer immune responses. However, delivering heat precisely to tumor tissue while sparing surrounding healthy tissue remains a significant challenge. Traditional hyperthermia methods, such as isolated limb perfusion, require complex, invasive procedures and carry substantial risk of local toxicity and patient morbidity. In contrast, photothermal therapy using gold nanoparticles activated by near-infrared (NIR) light has emerged as a promising, less invasive strategy for achieving localized hyperthermia. Gold nanorods (GNRs), in particular, exhibit tunable optical properties and high photothermal conversion efficiency, making them ideal candidates for precise thermal modulation of tumor sites. Although this technique has shown considerable promise, especially for superficial and accessible tumors, reproducible delivery, spatial confinement, and safety remain active areas of refinement. In this protocol, we present our validated and optimized method for achieving localized, mild hyperthermia using intratumoral injection of biocompatible GNRs followed by short-duration, targeted NIR laser exposure. This approach enables rapid, controllable heating within the therapeutic range, promoting immunogenic tumor cell death and stimulating innate immune responses, mechanisms particularly relevant for immunologically "cold" tumors. Real-time temperature monitoring and local delivery ensure reproducibility, safety, and minimal systemic exposure. This streamlined protocol offers a robust and accessible platform for preclinical studies, supporting broader efforts to harness mild hyperthermia in cancer immunotherapy.